1-Hexyl-3-methyl-imidazolium chloride, min. 98%, 25 g, glass packaging

Tert-butyl methyl(2-methylpiperidin-4-yl)carbamate, 97%, 100mg

7-Bromo-6-methoxyquinoline, 98%, 1g

5-bromo-2,4-dimethoxybenzaldehyde, 95.0%, 25g

2-Fluoro-4-ethoxycarbonylphenylboronic acid, 95.0%, 5g

(R)-Methyl 2-acetamidopropanoate, 95.0%, 5g

6,7-Difluoro-3,4-dihydro-2H-quinoxaline-1-carboxylic acid tert-butyl ester, 96%, 250mg

5-(4-Methylphenyl)-1,3-oxazole, 97%, 10g

TERT-BUTYL 4-((4-(HYDROXYMETHYL)PIPERIDIN-1-YL)METHYL)BENZOATE, 90.0%, 500mg

2-Bromo-1-fluoro-4-methoxybenzene, 95.0%, 1g

1-Methoxypentane-2,4-dione, 95.0%, 1g

4-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine, 97%, 250mg

Microliter syringe GASTIGHT® series 1700 Point type 2, 25 µl, 1702 RN, 1 piece